Addison Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Addison Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-400	Closed	-$3K	–	787
2022 Q3	$3K	Buy	+400	New	+$3.46K	﹤0.01%	528

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Addison Advisors's AUPH Position: Q4 2022 in Review

Addison Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2022, closing a stake of 400 shares — an estimated $3K sold.

Addison Advisors first reported a position in AUPH in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 192 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

Addison Advisors reported no remaining Aurinia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Addison Advisors sold 400 Aurinia Pharmaceuticals shares in Q4 2022, an estimated $3K.
Addison Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Addison Advisors's Aurinia Pharmaceuticals position peaked at $3K in Q3 2022.
192 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on Addison Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.